A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

Table 4 Change in IOP (mmHg) from baseline at weeks 1 to 3 (worse eye, ANCOVA, PP population)

	Latanoprost concentration (μg/mL)
	50	75	100	125
Week 1
8 a.m. IOP
N	69	66	71	68
LS mean change (mmHg)*	−9.11	−8.38	−8.85	−8.40
Adjusted difference in LS mean ± SEM^†		0.73 ± 0.50	0.25 ± 0.50	0.71 ± 0.50
(90% CI)		(−0.10, 1.57)	(−0.57, 1.07)	(−0.11, 1.54)
p-value^‡		0.926	0.696	0.922
4 p.m. IOP
N	69	66	71	68
LS mean change (mmHg)*	−8.07	−7.63	−8.04	−7.46
Adjusted difference in LS mean ± SEM^†		0.44 ± 0.48	0.03 ± 0.47	0.61 ± 0.47
(90% CI)		(−0.35, 1.22)	(−0.74, 0.79)	(−0.17, 1.38)
p-value^‡		0.820	0.522	0.902
Week 2
8 a.m. IOP
N	69	66	71	68
LS mean change (mmHg)*	−9.29	−9.56	−9.31	−9.05
Adjusted difference in LS mean ± SEM^†		−0.27 ± 0.44	−0.02 ± 0.43	0.24 ± 0.44
(90% CI)		(−1.00, 0.46)	(−0.73, 0.70)	(−0.49, 0.96)
p-value^‡		0.269	0.485	0.705
4 p.m. IOP
N	69	66	71	67
LS mean change (mmHg)*	−8.28	−8.19	−8.21	−7.65
Adjusted difference in LS mean ± SEM^†		0.08 ± 0.41	0.07 ± 0.40	0.63 ± 0.41
(90% CI)		(−0.60, 0.76)	(−0.60, 0.73)	(−0.04, 1.30)
p-value^‡		0.578	0.565	0.939
Week 3
8 a.m. IOP
N	68	65	71	66
LS mean change (mmHg)*	−9.68	−9.72	−9.79	−9.15
Adjusted difference in LS mean ± SEM^†		−0.04 ± 0.46	−0.12 ± 0.45	0.53 ± 0.45
(90% CI)		(−0.79, 0.71)	(−0.85, 0.62)	(−0.22, 1.28)
p-value^‡		0.463	0.396	0.879
4 p.m. IOP
N	68	64	71	66
LS mean change (mmHg)*	−8.61	−8.60	−8.65	−8.06
Adjusted difference in LS mean ± SEM^†		0.01 ± 0.45	−0.04 ± 0.44	−0.55 ± 0.45
(90% CI)		(−0.73, 0.76)	(−0.78, 0.68)	(−0.18, 1.29)
p-value^‡		0.512	0.464	0.892

ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
*Adjusting for baseline IOP (covariate) with dose group and center as factors.
^†Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
^‡ One-sided p-value.

ISSN: 1471-2415